drugset
drugset / Trial / NCT05702983

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

NCT05702983 ↗

Phase 1 Completed 20 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

An Open-label, Single-ascending dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects

Timeline

Start
2023-01-31
Primary completion
2023-04-11
Completion
2023-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject GREZIPRUBART Monoclonal antibody — Subcutaneous

Indications

anti-neutrophil cytoplasmic antibody-associated vasculitis